Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect of TGRX-678 in Healthy Subjects
NCT06697899Phase 1Completed
- Sponsor
- Shenzhen TargetRx
- Start
- Nov 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TGRX-678 in chronic myeloid leukemia (CML) (3 arms), sponsored by Shenzhen TargetRx. Primary endpoints: Plasma Tmax, Plasma Tlag and 6 more. Started Nov 2024; status: completed.
02
Drugs
TGRX-678
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT06697899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06697899.